Comparative Pharmacology
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus THYREL TRH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus THYREL TRH.
AMINOHIPPURATE SODIUM vs THYREL TRH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminohippurate sodium is a diagnostic agent used to measure effective renal plasma flow (ERPF) by competitive inhibition of tubular secretion of para-aminohippurate (PAH) via organic anion transporters (OAT1 and OAT3) in the proximal tubule, allowing clearance calculations.
Synthetic thyrotropin-releasing hormone (TRH) that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary.
For measurement of effective renal plasma flow (ERPF): 0.2 mL/kg of a 20% solution (40 mg/kg) administered intravenously over 1-2 minutes, followed by continuous intravenous infusion of 0.5 mL/min of a solution containing 4.5 g aminohippurate sodium in 500 mL normal saline (9 mg/mL) to maintain stable plasma levels.
Adult: 500 mcg IV bolus over 15-30 seconds; may repeat once after 15-30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5–1.0 hour; used to measure effective renal plasma flow (ERPF).
Terminal elimination half-life is approximately 5–6 minutes in healthy adults. This short half-life reflects rapid enzymatic degradation and renal clearance, requiring rapid intravenous administration for diagnostic thyroid stimulation.
Primarily renal: ~90% excreted unchanged by tubular secretion; <5% fecal.
Primarily renal excretion of intact TRH and metabolites (deamido-TRH and acid-TRH). Approximately 90% of administered radioactivity is recovered in urine within 24 hours. Biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Diagnostic Agent
Diagnostic Agent